Evidence map›Paper›PMID 30074634›Full record

ReviewHematological oncology2018

Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms.

Tariq I Mughal, Thomas Lion, Omar Abdel-Wahab, Ruben Mesa, Robyn M Scherber, Danilo Perrotti, Michael Mauro, Srdan Verstovsek, Giuseppe Saglio, Richard A Van Etten and 1 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Hematological oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 3 countries.

Tariq I MughalTufts University Cancer Center, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1005-7724
Thomas LionChildren's Cancer Research Institute, Medical University of Vienna, Vienna, Austria.
Omar Abdel-WahabMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Ruben MesaUT Health San Antonio Cancer Center, San Antonio, TX, USA.
Robyn M ScherberOregan Health and Science University, Portland, OR, USA.
Danilo PerrottiGreenebaum Cancer Center, University of Maryland, Baltimore, MD, USA.
Michael MauroMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Srdan VerstovsekMD Anderson Cancer Center, Houston, TX, USA.
Giuseppe SaglioOrbassano University Hospital, Turin, Italy.
Richard A Van EttenUniversity of California Irvine, Irvine, CA, USA.
Robert KralovicsResearch Center for Molecular Medicine of the Austrian Academy of Science, Vienna, Austria.
Memorial Sloan Kettering Cancer Center · USAustrian Academy of Sciences · ATCancer Research Institute of the Slovak Academy of Sciences · SKOregon Health & Science University · USThe University of Texas Health Science Center at San Antonio · USThe University of Texas MD Anderson Cancer Center · USTufts University · USUniversity of California, Irvine · USUniversity of Maryland, Baltimore · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lei Zheng · 1991 to 2026
$59.1M
Alpine Oncology FoundationIncyte CorporationNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA054174Novartis OncologyRoche Pharma
6 · The paper itself

Abstract

Following the 47th American Society of Hematology Meeting in 2005, the late John Goldman and Tariq Mughal commenced a conference, the 1st Post-ASH Workshop, which brought together clinicians and scientists, to accelerate the adoption of new therapies for patients with myeloproliferative neoplasms (MPNs). The concept began with recognition of the CML success story following imatinib therapy, the discovery of JAK2

Indexed as

Hematologic NeoplasmsMyeloproliferative DisordersAmino Acid SubstitutionFusion Proteins, bcr-ablHumansImmunotherapyJanus Kinase 2Mutation, MissensePrecision MedicineTranslational Research, BiomedicalBCR-ABL1 fusion protein, humanFusion Proteins, bcr-ablJAK2 protein, humanJanus Kinase 2Chronic myeloroliferative neoplasmsgenomicsimmunotherapytreatment

Identifiers

PMID30074634
PMCPMC6613211
OpenAlexW2885923669

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.